Danazol

openFDA / DailyMed US prescribing information (danazol capsules, Chartwell RX) - no UK SPC was available in this bundle, so the regimen must be checked against the UK SPC before publication. ENDOMETRIOSIS: the 800 mg starting dose achieves amenorrhoea and rapid response to painful symptoms most reliably; gradual downward titration to a dose sufficient to maintain amenorrhoea may be considered depending on patient response. For mild cases the initial daily dose of 200-400 mg in two divided doses may be adjusted depending on response. Therapy should begin during menstruation; otherwise appropriate tests should be performed to ensure the patient is not pregnant while on therapy. It is essential that therapy continues uninterrupted for 3 to 6 months, but it may be extended to 9 months if necessary. After termination of therapy, if symptoms recur, treatment can be reinstituted. HEREDITARY ANGIOEDEMA: dosage requirements for continuous treatment should be individualised on the basis of clinical response; it is recommended that the patient be started on 200 mg two or three times a day, and after a favourable initial response is obtained in terms of prevention of oedematous attacks the continuing dosage should be determined by decreasing the dose by 50% or less at intervals of one to three months or longer, depending on the pre-treatment attack frequency. If an attack occurs, the daily dosage may be increased by up to 200 mg. During the dose-adjusting phase, monitor the response closely, particularly if the patient has a history of airway involvement. SCOPE LIMIT: the fetched label does not describe a cyclical mastalgia regimen - the mastalgia dosing shown on this page is not covered by this source. Monitor for hepatic dysfunction by laboratory tests; hepatic dysfunction with reversible elevated serum enzymes and/or jaundice has been reported at daily doses of 400 mg or more.